Catheter Precision Financials

VTAK

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE March

This page shows Catheter Precision (VTAK) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Catheter Precision has an operating margin of -2581.6%, meaning the company retains $-2582 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -2676.9% the prior year.

Growth

100

Catheter Precision's revenue surged 95.0% year-over-year to $819K, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Catheter Precision carries a low D/E ratio of 0.18, meaning only $0.18 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 98/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Catheter Precision's current ratio of 0.10 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 0/100, which could limit financial flexibility.

Cash Flow

While Catheter Precision generated -$8.3M in operating cash flow, capex of $17K consumed most of it, leaving -$8.3M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Catheter Precision generates a -243.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -141.6% the prior year.

Piotroski F-Score Weak

3/9

Catheter Precision passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

0.48x

For every $1 of reported earnings, Catheter Precision generates $0.48 in operating cash flow (-$8.3M OCF vs -$17.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-3523.8x

Catheter Precision earns $-3523.8 in operating income for every $1 of interest expense (-$21.1M vs $6K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$819K

YoY+95.0%

5Y CAGR+25.9%

Catheter Precision generated $819K in revenue in fiscal year 2025. This represents an increase of 95.0% from the prior year.

EBITDA

-$19.0M

YoY-108.3%

Catheter Precision's EBITDA was -$19.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 108.3% from the prior year.

Net Income

-$17.2M

YoY-3.2%

Catheter Precision reported -$17.2M in net income in fiscal year 2025. This represents a decrease of 3.2% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

-$8.3M

YoY+11.0%

Catheter Precision generated -$8.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 11.0% from the prior year.

Cash & Debt

$88K

YoY-96.9%

5Y CAGR-67.4%

Catheter Precision held $88K in cash against $1.3M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

Catheter Precision had 3M shares outstanding in fiscal year 2025. This represents an increase of 539.1% from the prior year.

Margins & Returns

Gross Margin

92.3%

YoY+2.3pp

5Y CAGR+830.9pp

Catheter Precision's gross margin was 92.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.3 percentage points from the prior year.

Operating Margin

-2581.6%

YoY+95.3pp

5Y CAGR+11086.8pp

Catheter Precision's operating margin was -2581.6% in fiscal year 2025, reflecting core business profitability. This is up 95.3 percentage points from the prior year.

Net Margin

-2098.0%

YoY+1864.6pp

5Y CAGR+11818.9pp

Catheter Precision's net profit margin was -2098.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 1864.6 percentage points from the prior year.

Return on Equity

-243.6%

YoY-102.0pp

5Y CAGR-73.1pp

Catheter Precision's ROE was -243.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 102.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$862K

YoY+216.9%

5Y CAGR-37.4%

Catheter Precision invested $862K in research and development in fiscal year 2025. This represents an increase of 216.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$17K

YoY-74.6%

5Y CAGR-24.0%

Catheter Precision invested $17K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 74.6% from the prior year.

VTAK Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$819K+95.0%	$420K-5.0%	$442K+3057.1%	$14K-36.4%	$22K-91.5%	$259K
Cost of Revenue	$63K+50.0%	$42K+40.0%	$30K-81.4%	$161K-89.7%	$1.6M-28.2%	$2.2M
Gross Profit	$756K+100.0%	$378K-8.3%	$412K+380.3%	-$147K+90.4%	-$1.5M+19.6%	-$1.9M
R&D Expenses	$862K+216.9%	$272K-42.7%	$475K-92.6%	$6.4M-47.8%	$12.3M+36.8%	$9.0M
SG&A Expenses	$12.1M+6.4%	$11.3M-33.7%	$17.1M+5.4%	$16.3M+5.0%	$15.5M-36.9%	$24.5M
Operating Income	-$21.1M-88.1%	-$11.2M+85.6%	-$78.1M-189.7%	-$27.0M+7.9%	-$29.3M+17.3%	-$35.4M
Interest Expense	$6K	N/A	N/A	N/A	N/A	$108K
Income Tax	-$1.8M-157.6%	$3.1M	$0-100.0%	$3K-25.0%	$4K-42.9%	$7K
Net Income	-$17.2M-3.2%	-$16.6M+76.4%	-$70.6M-162.7%	-$26.9M-7.2%	-$25.1M+30.4%	-$36.0M
EPS (Diluted)	N/A	N/A	N/A	$-25.98	$-248.22	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$226K+6.6%	$212K+48.3%	$143K-4.0%	$149K+55.2%	$96K+3.2%	$93K+13.4%	$82K-35.9%	$128K
Cost of Revenue	$18K+28.6%	$14K+27.3%	$11K0.0%	$11K+10.0%	$10K-37.5%	$16K+220.0%	$5K-28.6%	$7K
Gross Profit	$208K+5.1%	$198K+50.0%	$132K-4.3%	$138K+60.5%	$86K+11.7%	$77K0.0%	$77K-36.4%	$121K
R&D Expenses	$276K+78.1%	$155K+50.5%	$103K+13.2%	$91K+44.4%	$63K-22.2%	$81K+118.9%	$37K+436.4%	-$11K
SG&A Expenses	$3.0M+2.5%	$2.9M-17.3%	$3.5M+12.5%	$3.1M+7.5%	$2.9M+6.2%	$2.7M+2.1%	$2.7M-2.7%	$2.7M
Operating Income	-$3.0M+35.5%	-$4.7M-31.1%	-$3.6M-17.2%	-$3.1M-6.7%	-$2.9M-5.2%	-$2.7M-3.9%	-$2.6M-0.7%	-$2.6M
Interest Expense	N/A	N/A	N/A	N/A	$32K	N/A	N/A	N/A
Income Tax	$78K+108.2%	-$950K-31.2%	-$724K-123.0%	$3.1M	$0	$0	$0	$0
Net Income	-$2.3M+55.9%	-$5.1M-26.3%	-$4.0M+28.1%	-$5.6M-36.6%	-$4.1M+2.4%	-$4.2M-57.8%	-$2.7M-299.9%	-$669K
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

VTAK Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$15.9M-42.9%	$27.8M-9.6%	$30.7M+82.6%	$16.8M-20.0%	$21.0M-37.1%	$33.4M
Current Assets	$390K-88.2%	$3.3M-20.9%	$4.2M-75.3%	$16.8M-1.5%	$17.1M-38.1%	$27.6M
Cash & Equivalents	$88K-96.9%	$2.9M-19.4%	$3.6M-77.5%	$15.9M+5.4%	$15.0M-37.1%	$23.9M
Inventory	$86K+160.6%	$33K-25.0%	$44K	$0-100.0%	$986K+12.4%	$877K
Accounts Receivable	$155K+121.4%	$70K-48.9%	$137K	$0-100.0%	$21K-12.5%	$24K
Goodwill	N/A	N/A	$0	$0	N/A	N/A
Total Liabilities	$9.2M-42.5%	$16.0M+67.8%	$9.5M+26.0%	$7.6M+2.8%	$7.4M-40.0%	$12.3M
Current Liabilities	$3.9M+75.2%	$2.2M-9.8%	$2.5M-67.4%	$7.6M+40.6%	$5.4M-30.6%	$7.8M
Long-Term Debt	$1.3M	N/A	N/A	N/A	N/A	N/A
Total Equity	$7.1M-40.0%	$11.8M-44.5%	$21.2M+128.9%	$9.3M-32.3%	$13.7M-35.3%	$21.1M
Retained Earnings	-$309.5M-5.9%	-$292.4M-6.0%	-$275.7M-34.4%	-$205.1M-15.1%	-$178.3M-16.4%	-$153.2M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$25.5M-0.4%	$25.6M+3.1%	$24.8M-10.7%	$27.8M+3.8%	$26.7M+1.8%	$26.3M-6.3%	$28.0M-8.8%	$30.7M
Current Assets	$2.5M+20.6%	$2.0M+139.6%	$854K-74.1%	$3.3M+92.1%	$1.7M+341.8%	$388K-80.1%	$2.0M-53.0%	$4.2M
Cash & Equivalents	$1.1M+28.3%	$838K+86.2%	$450K-84.3%	$2.9M+126.6%	$1.3M+7825.0%	$16K-98.9%	$1.5M-58.2%	$3.6M
Inventory	$34K-29.2%	$48K-32.4%	$71K+115.2%	$33K+3.1%	$32K-49.2%	$63K0.0%	$63K+43.2%	$44K
Accounts Receivable	$123K+7.0%	$115K+35.3%	$85K+21.4%	$70K-34.6%	$107K+1.9%	$105K+43.8%	$73K-46.7%	$137K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Total Liabilities	$19.0M+0.1%	$19.0M+12.6%	$16.9M+5.4%	$16.0M+15.0%	$13.9M+16.5%	$11.9M+25.8%	$9.5M-0.5%	$9.5M
Current Liabilities	$5.3M+14.7%	$4.6M+13.5%	$4.1M+83.4%	$2.2M-13.8%	$2.6M-22.1%	$3.3M+41.2%	$2.4M-4.9%	$2.5M
Long-Term Debt	$1.5M0.0%	$1.5M	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$6.8M-0.1%	$6.8M-14.2%	$7.9M-32.7%	$11.8M-8.3%	$12.8M-10.4%	$14.3M-22.7%	$18.5M-12.6%	$21.2M
Retained Earnings	-$303.8M-0.7%	-$301.5M-1.7%	-$296.4M-1.4%	-$292.4M-2.0%	-$286.7M-1.5%	-$282.6M-1.5%	-$278.4M-1.0%	-$275.7M

VTAK Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$8.3M+10.5%	-$9.3M+55.0%	-$20.6M+8.6%	-$22.6M+18.3%	-$27.6M+2.4%	-$28.3M
Capital Expenditures	$17K-74.6%	$67K-11.8%	$76K+347.1%	$17K-93.6%	$265K+295.5%	$67K
Free Cash Flow	-$8.3M+11.0%	-$9.3M+54.9%	-$20.7M+8.4%	-$22.6M+19.0%	-$27.9M+1.7%	-$28.4M
Investing Cash Flow	$167K+349.3%	-$67K-9.8%	-$61K-390.5%	$21K-99.4%	$3.8M-76.1%	$15.9M
Financing Cash Flow	$5.3M-38.2%	$8.6M+3.1%	$8.4M-64.1%	$23.4M+56.1%	$15.0M-31.0%	$21.7M
Dividends Paid	N/A	N/A	$800K	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$2.2M+3.5%	-$2.3M+3.2%	-$2.3M+18.4%	-$2.9M-3.5%	-$2.8M-63.1%	-$1.7M+12.6%	-$1.9M-2.8%	-$1.9M
Capital Expenditures	$0-100.0%	$7K-30.0%	$10K	$0	$0-100.0%	$45K+104.5%	$22K+22.2%	$18K
Free Cash Flow	-$2.2M+3.8%	-$2.3M+3.3%	-$2.3M+18.0%	-$2.9M-3.5%	-$2.8M-58.9%	-$1.7M+11.3%	-$2.0M-3.0%	-$1.9M
Investing Cash Flow	-$28K-115.4%	-$13K-30.0%	-$10K	$0	$0+100.0%	-$45K-104.5%	-$22K-22.2%	-$18K
Financing Cash Flow	$2.4M-8.1%	$2.7M+3652.0%	-$75K-101.7%	$4.5M+11.2%	$4.0M+1405.6%	$267K+342.7%	-$110K-2.8%	-$107K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

VTAK Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	92.3%+2.3pp	90.0%-3.2pp	93.2%+1143.2pp	-1050.0%+5940.9pp	-6990.9%-6252.3pp	-738.6%
Operating Margin	-2581.6%+95.3pp	-2676.9%+14997.1pp	-17674.0%+174904.6pp	-192578.6%-59551.3pp	-133027.3%-119358.9pp	-13668.3%
Net Margin	-2098.0%+1864.6pp	-3962.6%+12003.9pp	-15966.5%+175926.3pp	-191892.9%-77938.3pp	-113954.5%-100037.6pp	-13917.0%
Return on Equity	-243.6%-102.0pp	-141.6%+191.4pp	-333.0%-42.9pp	-290.1%-106.8pp	-183.3%-12.9pp	-170.4%
Return on Assets	-108.3%-48.4pp	-59.9%+169.7pp	-229.6%-70.0pp	-159.6%-40.4pp	-119.1%-11.3pp	-107.8%
Current Ratio	0.10-1.4	1.48-0.2	1.68-0.5	2.22-0.9	3.17-0.4	3.56
Debt-to-Equity	0.18-1.2	1.36+0.9	0.45-0.4	0.82+0.3	0.54-0.0	0.58
FCF Margin	-1015.0%+1208.3pp	-2223.3%+2458.8pp	-4682.1%+156639.3pp	-161321.4%-34548.7pp	-126772.7%-115818.7pp	-10954.0%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	92.0%-1.4pp	93.4%+1.1pp	92.3%-0.3pp	92.6%+3.0pp	89.6%+6.8pp	82.8%-11.1pp	93.9%-0.6pp	94.5%
Operating Margin	-1336.7%+873.6pp	-2210.4%+289.6pp	-2500.0%-452.3pp	-2047.7%+930.5pp	-2978.1%-56.6pp	-2921.5%+268.7pp	-3190.2%-1161.3pp	-2028.9%
Net Margin	-996.0%+1413.9pp	-2409.9%+418.8pp	-2828.7%+948.5pp	-3777.2%+514.5pp	-4291.7%+246.0pp	-4537.6%-1275.4pp	-3262.2%-2739.5pp	-522.7%
Return on Equity	-33.2%+42.1pp	-75.3%-24.1pp	-51.1%-3.2pp	-47.9%-15.8pp	-32.1%-2.6pp	-29.5%-15.0pp	-14.4%-11.3pp	-3.2%
Return on Assets	-8.8%+11.1pp	-20.0%-3.7pp	-16.3%+4.0pp	-20.3%-4.9pp	-15.4%+0.7pp	-16.1%-6.5pp	-9.6%-7.4pp	-2.2%
Current Ratio	0.46+0.0	0.44+0.2	0.21-1.3	1.48+0.8	0.66+0.5	0.12-0.7	0.83-0.9	1.68
Debt-to-Equity	0.220.0	0.22-1.9	2.13+0.8	1.36+0.3	1.09+0.3	0.83+0.3	0.51+0.1	0.45
FCF Margin	-965.9%+104.8pp	-1070.8%+571.2pp	-1642.0%+280.2pp	-1922.1%+961.2pp	-2883.3%-1010.2pp	-1873.1%+522.0pp	-2395.1%-905.3pp	-1489.8%

Note: The current ratio is below 1.0 (0.10), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Nuwellis Inc NUWE

$2.4M

Bone Biologics Corp BBLG

$2.0M

Bluejay Diagnostics Inc BJDX

$1.9M

Venus Concept Inc VERO

$2.1M

Nanovibronix Inc NAOV

$4.4M

Frequently Asked Questions

What is Catheter Precision's annual revenue?

Catheter Precision (VTAK) reported $819K in total revenue for fiscal year 2025. This represents a 95.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Catheter Precision's revenue growing?

Catheter Precision (VTAK) revenue grew by 95% year-over-year, from $420K to $819K in fiscal year 2025.

Is Catheter Precision profitable?

No, Catheter Precision (VTAK) reported a net income of -$17.2M in fiscal year 2025, with a net profit margin of -2098.0%.

What is Catheter Precision's EBITDA?

Catheter Precision (VTAK) had EBITDA of -$19.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Catheter Precision have?

As of fiscal year 2025, Catheter Precision (VTAK) had $88K in cash and equivalents against $1.3M in long-term debt.

What is Catheter Precision's gross margin?

Catheter Precision (VTAK) had a gross margin of 92.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Catheter Precision's operating margin?

Catheter Precision (VTAK) had an operating margin of -2581.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Catheter Precision's net profit margin?

Catheter Precision (VTAK) had a net profit margin of -2098.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Catheter Precision's return on equity (ROE)?

Catheter Precision (VTAK) has a return on equity of -243.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Catheter Precision's free cash flow?

Catheter Precision (VTAK) generated -$8.3M in free cash flow during fiscal year 2025. This represents a 11.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Catheter Precision's operating cash flow?

Catheter Precision (VTAK) generated -$8.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Catheter Precision's total assets?

Catheter Precision (VTAK) had $15.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Catheter Precision's capital expenditures?

Catheter Precision (VTAK) invested $17K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Catheter Precision spend on research and development?

Catheter Precision (VTAK) invested $862K in research and development during fiscal year 2025.

How many shares does Catheter Precision have outstanding?

Catheter Precision (VTAK) had 3M shares outstanding as of fiscal year 2025.

What is Catheter Precision's current ratio?

Catheter Precision (VTAK) had a current ratio of 0.10 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Catheter Precision's debt-to-equity ratio?

Catheter Precision (VTAK) had a debt-to-equity ratio of 0.18 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Catheter Precision's return on assets (ROA)?

Catheter Precision (VTAK) had a return on assets of -108.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Catheter Precision's cash runway?

Based on fiscal year 2025 data, Catheter Precision (VTAK) had $88K in cash against an annual operating cash burn of $8.3M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Catheter Precision's Piotroski F-Score?

Catheter Precision (VTAK) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Catheter Precision's earnings high quality?

Catheter Precision (VTAK) has an earnings quality ratio of 0.48x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Catheter Precision cover its interest payments?

Catheter Precision (VTAK) has an interest coverage ratio of -3523.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Catheter Precision?

Catheter Precision (VTAK) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.